Drug Trial Radar · NCT06555549
Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain in Primary Dysmenorrhea: a Pilot Study
Last checked: Nov 19, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 2024
Primary completion
Sep 2025
Study completion Feb 2026
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 16 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the preliminary efficacy and safety of DEH113 in the Treatment of Menstrual Cramps Pain Associated with Primary Dysmenorrhea.
Conditions
- Primary Dysmenorrhea
Interventions
DEH113Drug
tablets
PlaceboDrug
tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sum of Total Pain Relief (TOTPAR) over 0-4, 0-6 and 0-8 hours post-doseTime frame: 4, 6 and 8 hours post-dose
- Sum of Pain Intensity Difference (SPID) over 4, 6 and 8 hours post-doseTime frame: 4, 6 and 8 hours post-dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.